COURSE:

This week, you will create a Medication Study Guide to share with your peers. This guide is intended to be a useful learning tool for you to use as you prepare for your clinical courses.

You will be assigned one of the following medications to create your guide:

Chlorpromazine	Fluphenazine	Haloperidol	Loxapine	Perphenazine
Aripiprazole	Asenapine	Clozapine	Iloperidone	Olanzapine
Paliperidone	Quetiapine	Risperidone	Ziprasidone	Lurasidone
Brexpiprazole	Cariprazine	Lumateperone	Benztropine	Propranolol
Deutetrabenazine	Valbenazine

The Assignment

Create a 3- to 4-page (excluding visual elements) Medication Study Guide for your assigned psychotropic medication agents that may be utilized by you and colleagues for study. Your medication guide should be in the form of an outline and should include a title page, citations, and references. You should incorporate visual elements, such as concept maps, charts, diagrams, images, color coding, mnemonics, and/or flashcards. Be creative!

Note: Your Medication Study Guide should not be in the format of an APA paper.

Also Note: Your guide should be informed by the FDA-Approved and Evidenced-Based, Clinical Practice Guidelines Research.

Areas of importance that you should address—but are not limited to—include:

Title page
Description of the psychopharmacological medication agent, including brand and generic names, as well as appropriate FDA indication uses
Any supporting, valid, and reliable research for non-FDA uses
Drug classification
The medication mechanism of action
The medication pharmacokinetics
The medication pharmacodynamics
Appropriate dosing, administration route, and any considerations for dosing alterations
Considerations of use and dosing in specific specialty populations, such as children, adolescents, elderly, pregnant people, those exhibiting suicidal behaviors, etc.
Definition of half-life, why half-life is important, and the half-life for your assigned medication
Side effects/adverse reactions potential
Discuss clinical concerns with EPS and Tardive Dyskinesia
Note: Be sure to include screening tools that would be utilized.
Contraindications for use including significant drug to drug interactions
Overdose considerations
Diagnostics and labs monitoring comorbidities considerations
Legal, ethical, and social considerations
Pertinent patient education considerations
References page

Solution

Patient Medication Guide: Deutetrabenazine

Description of Deutetrabenazine	Brand name : Austedo, Austedo XR Generic name: Deutetrabenazine FDA indication: v It is used to treat chorea that is associated with Huntington’s disease. v Also approved for tardive dyskinesia in adult patients (U.S. Food and Drug Administration, n.d
Non-FDA uses	v Studies have also reported that it can be used to treat tics associated with Tourette syndrome (Coffey et al., 2021)
Drug classification	This drug is a vesicular monoamine transporter2 (VMAT2) inhibitor.
Mechanism of action	Works by reducing the action of the action of VMAT2 thereby reducing the levels of monoamines in the synaptic cleft. Ideally, VMAT2 is involved in the packaging of monoamines such as norepinephrine, serotonin, and dopamine into vesicles. Deutetrabenazine metabolites namely the αdihydrotetrabenazine [HTBZ] and β-HTBZ) are considered as reversible inhibitors of VMAT2. Therefore, they lead to a decrease in the uptake of monoamines into the synaptic vessels as well as depletion of the monoamine stores (FDA, n.d.)

…………………………………….$10

[Solved] NURS-6630N Week 7 Discussion/Assignment: Patient Medication Guide